Preferred Label : Anti-PD-L1/PD-L2 Bispecific Antibody IMGS-001;
NCIt synonyms : Anti-PD-L1/PD-L2 Antibody IMGS-001; Anti-PD-L1/anti-PD-L2 Bispecific Monoclonal Antibody IMGS-001;
NCIt definition : Fc-engineered bispecific monoclonal antibody targeting both immune checkpoint regulatory
proteins human programmed death-ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273), with
potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities.
Upon administration, anti-PD-L1/PD-L2 bispecific antibody IMGS-001 simultaneously
targets and binds to PD-L1 and PD-L2 expressed on tumor cells, immunosuppressive stromal
cells and endothelial cells. PD-L1 and PD-L2 binding by IMGS-001 prevents both PD-L1
and PD-L2 from binding to and activating their receptor programmed cell death 1 (PD-1;
PDCD1; CD279; programmed death-1). This abrogates PD-1-mediated signaling in T-cells
and PD-1-mediated T-cell inhibition. This activates cytotoxic T-lymphocytes and enhances
cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor
growth. In addition, IMGS-001 induces antibody-dependent cell-mediated cytotoxicity
(ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby killing PD-L1
and PD-L2-expressing cells in the tumor microenvironment (TME), and further abrogating
the immunosuppressive nature of the TME. PD-L1 and PD-L2 binding to PD-1 on activated
T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the
immune system and results in immune evasion.;
Molecule name : IMGS 001; IMGS-001;
Origin ID : C201236;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
